EP3672591
SYNERGISTIC ANTITUMOR EFFECT OF BCL-2 INHIBITOR COMBINED WITH RITUXIMAB AND/OR BENDAMUSTINE OR BCL-2 INHIBITOR COMBINED WITH CHOP
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
22.7.2019EP published:
14.2.2024EP application number:
19845466.2
EPO information:
European Patent Register
Max expiry date:
21.7.2039
Title in English:
SYNERGISTIC ANTITUMOR EFFECT OF BCL-2 INHIBITOR COMBINED WITH RITUXIMAB AND/OR BENDAMUSTINE OR BCL-2 INHIBITOR COMBINED WITH CHOPLanguage of the patent:
English
Timeline
Today
22.7.2019EP application
14.2.2024EP Publication
Owner
Name:
Ascentage Pharma (Suzhou) Co., Ltd.Address:
Unit 701, Building B7, 218 Xinghu Street Suzhou Industrial Park, Suzhou, Jiangsu 215000, CN
Inventor
Name:
YANG, DajunAddress:
Suzhou, Jiangsu 215000, CN
Name:
ZHAI, YifanAddress:
Suzhou, Jiangsu 215000, CN
Name:
WANG, GuangfengAddress:
Suzhou, Jiangsu 215000, CN
Priority
Number:
201810867252Date:
31.7.2018Country:
CN
Classification
Categories:
A61K 31/4184, A61K 39/395